Electrical cardioversion for atrial fibrillation. Are there indications left after the AFFIRM study?;Cardioversión eléctrica para la fibrilación auricular. ¿Existen aún indicaciones tras el estudio AFFIRM?

Revista Espanola de Cardiologia

Volumn 56, Issue 8, 2003, Pages 751-753

  Moro, Concepción ^a   Hernández Madrid, Antonio ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

CARDIOVERSION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE CLASSIFICATION; EDITORIAL; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HUMAN; HYPERTENSION; INCIDENCE; MEDICAL LITERATURE; MORTALITY; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT PLANNING;

EID: 0141669293     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050326     Document Type: Editorial

References (11)

1. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-33.
2. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation- Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000;356:1789-94.
3. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
4. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrythmia suppression after myocardial infarction. The Cardiac Arrythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989;321:406-12.
5. Julian DG, Camm AJ, Frangin G, Janse MJ, Muñoz A, Schwartz PJ, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
6. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82.
7. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-20.
8. Madrid AH, Bueno MG, Rebollo JM, Marin I, Peña G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation. a prospective and randomized study. Circulation 2002;106:331-6.
9. Vermes E, Tardif JC, Bourassa M, Racine N, Levesque S, White M, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the studies of left ventricular dysfuntion (SOLVD) trials. Circulation 2003;107:2926-31.
10. Moreno I, Caballero R, González T, Arias C, Iriepa I, et al. Effects of irbesartan on cloned potassium channels incolved in human cardiac repolorization. J Phamacol Exp Ther 2003;304:862-73.
11. Villacastín JP. Ablación percutánea de fibrilación auricular. Buenas perspectivas. Rev Esp Cardiol 2003;56:331-2.